FDA Regulatory Strategy & Designation Planning — agent trajectory for expert review

{
  "id": "ASSET-01",
  "name": "DLL3 CAR-T in relapsed/refractory ES-SCLC",
  "indication": "Extensive-stage small cell lung cancer (ES-SCLC), 3rd line+",
  "seriousness": "Serious / life-threatening (median OS in 3L+ SCLC is a few months).",
  "modality": "Autologous CAR-T cell therapy (regenerative medicine).",
  "unmet_need": "No approved targeted therapy in 3L+ SCLC; remaining options are low-response palliative chemo. Clear unmet need vs available therapy.",
  "available_therapy": "Topotecan / lurbinectedin / re-challenge chemo (ORR ~15-20%, not durable).",
  "clinical_evidence": "Phase 1/2: confirmed ORR 55% vs ~15-20% for available chemo, with early durability (several responders >6 months). Human data in hand.",
  "endpoint_type": "Surrogate (objective response rate) \u2014 OS not yet mature.",
  "prevalence_us": 35000,
  "pediatric": false,
  "phase": "Phase 1/2"
}

{
  "programs": [
    {
      "id": "fast_track",
      "name": "Fast Track",
      "type": "Development designation",
      "benefit": "Rolling review, more frequent FDA meetings/written communication, and eligibility for Accelerated Approval and Priority Review if criteria later met."
    },
    {
      "id": "breakthrough",
      "name": "Breakthrough Therapy (BTD)",
      "type": "Development designation",
      "benefit": "All Fast Track features PLUS intensive FDA guidance on efficient drug development starting as early as Phase 1, and organizational commitment (senior managers / cross-disciplinary review)."
    },
    {
      "id": "accelerated_approval",
      "name": "Accelerated Approval (AA)",
      "type": "Approval pathway",
      "benefit": "Approval can occur YEARS earlier, on the surrogate/intermediate endpoint, before overall-survival-type outcomes mature."
    },
    {
      "id": "priority_review",
      "name": "Priority Review",
      "type": "Review designation",
      "benefit": "Shortens the FDA REVIEW CLOCK to ~6 months (vs ~10 months standard)."
    },
    {
      "id": "rmat",
      "name": "Regenerative Medicine Advanced Therapy (RMAT)",
      "type": "Development designation (regenerative medicine)",
      "benefit": "All Breakthrough features (early intensive guidance) PLUS explicit eligibility for Accelerated Approval on surrogate/intermediate endpoints and flexible confirmatory-evidence options (e.g. real-world data, expanded registries)."
    },
    {
      "id": "orphan",
      "name": "Orphan Drug Designation",
      "type": "Incentive designation",
      "benefit": "7 years of orphan market exclusivity on approval, tax credits for clinical trials, and waiver of the (large) PDUFA application user fee."
    },
    {
      "id": "rare_pediatric",
      "name": "Rare Pediatric Disease (RPD) Designation + Priority Review Voucher",
      "type": "Incentive designation (pediatric)",
      "benefit": "On approval of the RPD product, the sponsor receives a TRANSFERABLE Priority Review Voucher (PRV) \u2014 sellable for ~$100M+ \u2014 redeemable to get Priority Review on any future application."
    }
  ],
  "ema_analogues": {
    "prime": "PRIME (PRIority MEdicines) \u2014 EMA's enhanced-support scheme, loosely analogous to Breakthrough Therapy; for medicines targeting an unmet need with early evidence of major therapeutic advantage. Often paired with conditional marketing authorisation.",
    "conditional_ma": "Conditional Marketing Authorisation \u2014 EMA analogue of Accelerated Approval; approval on less complete data for a serious/unmet-need condition, with an obligation to provide confirmatory comprehensive data post-authorisation.",
    "ema_orphan": "EU Orphan Designation \u2014 analogue of US Orphan Drug; prevalence threshold \u2264 5 in 10,000 in the EU, grants 10 years market exclusivity."
  },
  "note": "Designations are NOT mutually exclusive; a strong strategy stacks several. Use get_program_criteria for the full qualifying criteria of each program."
}

{
  "query": "small cell lung cancer",
  "count": 0,
  "precedents": [
    {
      "drug": "Tisagenlecleucel (Kymriah)",
      "indication": "Relapsed/refractory follicular lymphoma",
      "modality": "Autologous CAR-T",
      "designations": [
        "RMAT",
        "Accelerated Approval",
        "Orphan Drug",
        "Breakthrough Therapy (other indications)"
      ],
      "note": "RMAT granted on preliminary Phase 2 ELARA data (ORR ~86%); later accelerated approval on response endpoints with a confirmatory obligation. Canonical CAR-T regenerative-medicine pathway precedent."
    },
    {
      "drug": "Pembrolizumab (Keytruda)",
      "indication": "Advanced melanoma (initial) and many oncology indications",
      "modality": "Anti-PD-1 monoclonal antibody",
      "designations": [
        "Breakthrough Therapy",
        "Accelerated Approval",
        "Priority Review"
      ],
      "note": "Initial melanoma approval was Accelerated Approval on durable ORR (a surrogate), with confirmatory trials required; a textbook surrogate-endpoint AA precedent for a naked mAb in oncology."
    },
    {
      "drug": "Onasemnogene abeparvovec (Zolgensma)",
      "indication": "Spinal muscular atrophy (rare fatal pediatric neuromuscular disease)",
      "modality": "AAV gene therapy",
      "designations": [
        "RMAT",
        "Breakthrough Therapy",
        "Orphan Drug",
        "Rare Pediatric Disease PRV",
        "Priority Review"
      ],
      "note": "Rare fatal pediatric gene therapy that stacked regenerative-medicine, orphan, and rare-pediatric-disease incentives \u2014 the model for a fatal pediatric gene-therapy designation stack."
    },
    {
      "drug": "Zolbetuximab (Vyloy)",
      "indication": "CLDN18.2+ gastric/GEJ adenocarcinoma",
      "modality": "Naked monoclonal antibody",
      "designations": [
        "Orphan Drug (gastric)",
        "Priority Review"
      ],
      "note": "First-in-class naked mAb approved on a mature randomized endpoint \u2014 illustrates a non-regenerative asset using orphan + priority review rather than AA."
    }
  ],
  "note": "If no direct match, full precedent list returned for analogy."
}

{
  "id": "rmat",
  "name": "Regenerative Medicine Advanced Therapy (RMAT)",
  "type": "Development designation (regenerative medicine)",
  "criteria": [
    "Drug is a REGENERATIVE MEDICINE THERAPY (cell therapy, therapeutic tissue engineering, human cell/tissue product, or qualifying combination \u2014 e.g. CAR-T, gene therapy).",
    "Intended to treat, modify, reverse, or cure a SERIOUS or life-threatening condition.",
    "PRELIMINARY CLINICAL EVIDENCE indicates the drug has potential to address UNMET MEDICAL NEEDS for that condition."
  ],
  "benefit": "All Breakthrough features (early intensive guidance) PLUS explicit eligibility for Accelerated Approval on surrogate/intermediate endpoints and flexible confirmatory-evidence options (e.g. real-world data, expanded registries).",
  "timing": "With the IND or after; FDA responds within 60 days.",
  "gotcha": "It is the regenerative-medicine analogue of Breakthrough \u2014 ONLY for cell/gene/tissue products. A small molecule or naked mAb cannot get RMAT, even with great data."
}

{
  "id": "breakthrough",
  "name": "Breakthrough Therapy (BTD)",
  "type": "Development designation",
  "criteria": [
    "Drug treats a SERIOUS or life-threatening condition.",
    "PRELIMINARY CLINICAL EVIDENCE (i.e. human data, not just nonclinical) indicates the drug may demonstrate SUBSTANTIAL IMPROVEMENT over AVAILABLE THERAPY ...",
    "... on one or more CLINICALLY SIGNIFICANT ENDPOINT(s) (a durable, large effect \u2014 e.g. dramatic ORR/response vs a weak standard of care, or effect on a strong surrogate that represents a clear advance)."
  ],
  "benefit": "All Fast Track features PLUS intensive FDA guidance on efficient drug development starting as early as Phase 1, and organizational commitment (senior managers / cross-disciplinary review).",
  "timing": "Ideally by the end-of-Phase-2 meeting; FDA responds within 60 days.",
  "gotcha": "The differentiator from Fast Track is the EVIDENCE TYPE and SIZE: BTD needs PRELIMINARY CLINICAL evidence of SUBSTANTIAL (not just any) improvement over AVAILABLE therapy. Nonclinical-only assets do not qualify."
}

{
  "id": "accelerated_approval",
  "name": "Accelerated Approval (AA)",
  "type": "Approval pathway",
  "criteria": [
    "Drug treats a SERIOUS or life-threatening condition.",
    "Provides a MEANINGFUL ADVANTAGE over AVAILABLE THERAPY.",
    "Shows an effect on a SURROGATE ENDPOINT, or an INTERMEDIATE CLINICAL endpoint, that is REASONABLY LIKELY TO PREDICT clinical benefit (e.g. ORR/tumor shrinkage as a stand-in for survival)."
  ],
  "benefit": "Approval can occur YEARS earlier, on the surrogate/intermediate endpoint, before overall-survival-type outcomes mature.",
  "timing": "An approval pathway, discussed pre-NDA/BLA; not a 60-day designation.",
  "gotcha": "REQUIRES a confirmatory (Phase 4) trial to verify clinical benefit; the trial should generally be UNDERWAY at approval. If it fails, the drug can be withdrawn. Needs a SURROGATE/INTERMEDIATE endpoint \u2014 a fully mature OS readout is regular approval, not AA."
}

{
  "id": "fast_track",
  "name": "Fast Track",
  "type": "Development designation",
  "criteria": [
    "Drug treats a SERIOUS or life-threatening condition.",
    "Demonstrates potential to address an UNMET MEDICAL NEED, OR is a qualified infectious disease product.",
    "Evidence bar is LOW: nonclinical data, or a plausible mechanistic / early clinical rationale, is enough \u2014 no efficacy data required."
  ],
  "benefit": "Rolling review, more frequent FDA meetings/written communication, and eligibility for Accelerated Approval and Priority Review if criteria later met.",
  "timing": "Any time, with the IND or after; FDA responds within 60 days.",
  "gotcha": "Fast Track is about UNMET NEED + seriousness; it does NOT by itself speed the review clock \u2014 that is Priority Review."
}

{
  "id": "priority_review",
  "name": "Priority Review",
  "type": "Review designation",
  "criteria": [
    "Application is for a drug that, if approved, would be a SIGNIFICANT IMPROVEMENT in the safety or effectiveness of treatment, diagnosis, or prevention of a SERIOUS condition (or qualifies via a Priority Review Voucher)."
  ],
  "benefit": "Shortens the FDA REVIEW CLOCK to ~6 months (vs ~10 months standard).",
  "timing": "Decided at the time the marketing application (NDA/BLA) is filed.",
  "gotcha": "Acts only at REVIEW time on the FILED application \u2014 it does not affect the development program. A Rare Pediatric Disease PRV can also CONFER Priority Review on an unrelated product."
}